Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 5,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Terminated Phase 2 Interventional Results available

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

NCT03883607
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Elafibranor 80mg, Elafibranor 120mg
Drug
Lead sponsor
Genfit
Industry
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

NCT00545519
View directory record Official record
Conditions
Relapsed Or Refractory Multiple Myeloma
Interventions
thymoglobulin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 28, 2026, 5:10 PM EDT
Terminated Not applicable Interventional

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01962636
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Interventions
Fludarabine, Cyclophosphamide, Total Body Irradiation, Cyclosporine A, Mycophenylate mofetil, Umbilical cord blood
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

NCT01050764
View directory record Official record
Conditions
Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions
Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System
Drug · Device
Lead sponsor
Everett Meyer
Other
Eligibility
Up to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 28, 2026, 5:10 PM EDT
Not listed Phase 3 Interventional

Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

NCT00777244
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
MITOTANE
Drug
Lead sponsor
University of Turin, Italy
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

NCT02959164
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Sarcoma
Interventions
Decitabine, Gemcitabine
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 28, 2026, 5:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Memories of Fear and Safety in the Human Brain

NCT04975009
View directory record Official record
Conditions
Fear Anxiety, PTSD
Interventions
Fear conditioning
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 28, 2026, 5:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT04588545
View directory record Official record
Conditions
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions
Radiation Therapy, Pertuzumab, Trastuzumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Withdrawn Not applicable Interventional

Vestibular Implants Tested in Human Subjects

NCT04905472
View directory record Official record
Conditions
Vestibular Disorder, Vestibular Ataxia, Vestibular Loss, Bilateral
Interventions
Vestibular prosthesis/implant, Vestibular Implant Stimulation
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Testing a Self-Management App for Symptoms of Posttraumatic Stress

NCT04155736
View directory record Official record
Conditions
PTSD
Interventions
Renew
Behavioral
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Hispanic Secondary Stroke Prevention Initiative

NCT02251834
View directory record Official record
Conditions
Stroke
Interventions
Community Health Worker (CHW), usual care and health education brochures every 4 months.
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 28, 2026, 5:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Synergistic Activity of Human Milk Nutrients and Infant Cognition

NCT03838536
View directory record Official record
Conditions
Breastfeeding, Exclusive
Interventions
Whole Egg Powder, Egg White Powder
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Months to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT00402558
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Thymoglobulin, Busulfan, Fludarabine, Alloreactive NK Infusion, G-CSF, Tacrolimus, Methotrexate, Interleukin-2
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

NCT05064085
View directory record Official record
Conditions
Hormone Receptor-positive Breast Cancer
Interventions
Cemiplimab, Capecitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Text Messaging to Improve Adherence to Web-Based Cessation Treatment

NCT02585206
View directory record Official record
Conditions
Smoking Cessation
Interventions
Personalization, Integration, Dynamic Tailoring, Message Intensity, Optimal-Adherence Text
Behavioral
Lead sponsor
Truth Initiative
Other
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01647516
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 73 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
10
States / cities
Anaheim, California • La Jolla, California • Oceanside, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 28, 2026, 5:10 PM EDT
Not yet recruiting Not applicable Interventional

Supplemental Mobility

NCT07872384
View directory record Official record
Conditions
Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Interventions
High Intensity Rehabilitation, Safe Transfers and Mobility Program, Usual Care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial

NCT01492348
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Depression
Interventions
STEPS UP, OUC
Behavioral
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Fort Carson, Colorado • Fort Stewart, Georgia • Fort Campbell, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

NCT02681055
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions
MN-001
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Coronado, California • La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions

NCT03876106
View directory record Official record
Conditions
EGFR Inhibitor Induced Acneiform Lesions
Interventions
LUT014
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847
View directory record Official record
Conditions
Heart Failure
Interventions
Thyroid hormone T3, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Recruiting No phase listed Observational

Complex Adult Deformity Surgery (CADS)

NCT04194138
View directory record Official record
Conditions
Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
Interventions
Index or spine revision surgery for complex adult spinal deformity
Procedure
Lead sponsor
International Spine Study Group Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
17
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 28, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users

NCT01161485
View directory record Official record
Conditions
HIV Infections
Interventions
HIV Testing and Counseling, Contingency Management, Strengths-based case management
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 28, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

NCT06475235
View directory record Official record
Conditions
Lymphoma, Primary Central Nervous System Lymphoma
Interventions
Pembrolizumab, Methotrexate, Temozolomide, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 5:10 PM EDT